

Novel products, Research & Policy

by S@HRE

30 SEPTEMBER - 1 OCTOBER 2025 SATHENS Basil & Elise Goulandris Foundation

PRELIMINARY PROGRAMME

(Times featured are in Athens's time)

TUESDAY | 30.09.2025

09:30-10:00	REGISTRATIONS
10:00-11:00	SESSION OPENING REMARKS Goals of the 8th Summit on THR Organising Committee & SCOHRE Board Chairs: Ignatios Ikonomidis, Konstantinos Farsalinos, David T. Sweanor, J.D., Andrzej Fal
	OPENING SPEECH History and future of nicotine plus some learnings from the Swedish end-game Speaker: Karl Fagerstrom
11:00-11:30	KEYNOTE SPEECH Tobacco Harm Reduction Speaker: Stelios Kympouropoulos
	Chair: Ignatios Ikonomidis
11:30-12:00	BREAK
12:00-13:00	PANEL DISCUSSION European Policy and Public Health Chair: Andrzej Fal
	Speakers: Martin Smatana Ranko Stevanovic tba
13:00-13:45	SESSION IN GREEK - INTERPRETING AVAILABLE
	KEYNOTE SPEECH Greek New Legislation: 'Minors' protection from tobacco and alcohol products' Speaker: Christina-Maria Kravvari
	Chairs: Ignatios Ikonomidis, David T. Sweanor, J.D.
	DISCUSSION All Commentator: Anastasia Barbouni



Novel products, Research & Policy

by S@HRE

30 SEPTEMBER - 1 OCTOBER 2025 SATHENS Basil & Elise Goulandris Foundation

13:45-14:15	RESEARCH TRACK POSTER SESSION I Chair: Anastasia Barbouni
	 Epidemiology & Social Issues (Perception risk, Attractiveness etc.) - PP01 Toxicology and aerosol chemistry - Chemical composition of the aerosol, droplet size and distribution, temperature and toxicants, indoor air quality - PP02-PP04 Innovation & Novel Products - PP05
14:00-15:00	BREAK
15:00-16:00	SESSION Tobacco harm reduction in Africa: a diverse region in novel tobacco product control Chair: Solomon T. Rataemane Speakers: Tobacco Harm Reduction in Africa an in Limic: a public health requirement - Fares Mili Tobacco Harm Reduction Strategies in Africa: Realities and Perspectives - Imane Kendili Understanding nicotine addiction, neurobiology, and behavioural aspects - Michael Kariuki
16:00-17:30	 RESEARCH TRACK SESSION I Chair: Konstantinos Poulas Innovation & Novel Products - OP01 Epidemiology & Social Issues (Perception risk, Attractiveness etc.) - OP02-OP06 Biomarkers' evaluation in animal or human studies - OP07-OP08 Toxicology and aerosol chemistry - Chemical composition of the aerosol, droplet size and distribution, temperature and toxicants, indoor air quality - OP09 Regulatory issues - OP10 Educational issues in adolescence - OP11
17:30	COCKTAIL RECEPTION

WEDNESDAY | 01.10.2025

PANEL DISCUSSION

Consumer and healthcare professionals' misconceptions on the harms of nicotine Chair: Konstantinos Farsalinos

09:30-10:30

Speakers:

- Rohan Andrade De Sequeira
- Giovanni Li Volti
- Damian Sweeney



Novel products, Research & Policy

by S@HRE

30 SEPTEMBER - 1 OCTOBER 2025 SATHENS Basil & Elise Goulandris Foundation

10:30-11:00	KEYNOTE SPEECH The Framework Convention on Tobacco Control: A good idea gone wrong Speaker: Clive Bates Chair: Konstantinos Farsalinos
11:00-11:30	BREAK
11:30-12:30	PANEL DISCUSSION Public trust in health authorities and how actions on nicotine erode that trust Chair: David T. Sweanor, J.D. Speakers: Martin Cullip Filip Tokic Mary Stamp
12:30-14:00	SESSION Session on Consensus Chair: Lina Nikolopoulou Speakers: Italy - Pasquale Caponnetto Czech Republic - Lubos Petruzelka Panellists: Italy Francesco Fedele Czech Republic Jiri Votruba Greece Ignatios Ikonomidis
14:00-15:00	BREAK
14:00-15:00	RESEARCH TRACK POSTER SESSION II Chair: Fares Mili Preclinical evaluation - PP06 Clinical Assessment and Harm Reduction - PP07 Smoking cessation - PP08-PP11
15:00-16:00	SESSION Tobacco harm reduction in Asia: a diverse region in novel tobacco product control Chair: Sharifa Ezat Wan Puteh Speakers: The case of Malaysia - Vicknasingam Balasingam Kasinather The case of Hong Kong - Chung Hin Willy Wong The case of Philippines - Fernando Fernandez

8th Summit Tobacco Harm Reduction

Novel products, Research & Policy

by S@HRE

30 SEPTEMBER - 1 OCTOBER 2025 SATHENS Basil & Elise Goulandris Foundation

RESEARCH TRACK SESSION II Chair: Kallirhoe Kourea

16:00-17:30

- Preclinical evaluation OP12-OP13
- Clinical Assessment and Harm Reduction OP14-OP17
- Smoking cessation OP18-OP22